226 Studies Now Enrolling
Menu
Search
Status
Medical Condition
- Show all (116)
- Allergy, Asthma, & Immunology (1)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (6)
- Bone & Muscle (1)
- Cancer (65)
- (-) COVID-19 (Coronavirus) (2)
- Diabetes (1)
- Gastrointestinal and Digestive Diseases (1)
- Hair and Skin Disorders (3)
- Healthy Volunteers (11)
- Heart Disease (3)
- Infectious Disease (1)
- Kidney Disease (1)
- Lung Disease (5)
- Neurological Disorders (4)
- Obstetrics & Gynecology (2)
- Pediatrics (3)
- Psychiatric Disorders (1)
- Rehabilitation (1)
- (-) Transplant (2)
- Vascular Conditions (1)
Displaying 1 - 4 of 4
Condition: Transplant / Kidney Transplant
Investigator: Marcus Pereira, MD, MPH
Status: Closed
This purpose of this study is to understand the interaction between two different medications, tacrolimus and Paxlovid (nirmatrelvir/ritonavir), in patients who have had a kidney transplant and are being treated by their doctor for COVID-19 infection. Tacrolimus is an oral medication that is used standardly in kidney transplant recipients to prevent…
Condition: COVID-19 (Coronavirus)
Investigator: Ellen Morrison, MD, MPH
Status: Closed
We are conducting a CoVPN-funded study to understand if monoclonal antibodies can protect people exposed to SARS-COV-2 from developing the COVID-19 disease that it causes. If you live with someone recently diagnosed with COVID, you may be eligible to participate in one or more study visits. At each visit you will be asked to provide blood, nasal, and urine…
Condition: COVID-19 (Coronavirus)
Investigator: Deborah Theodore, MD
Status: Closed
The HERO program has two parts: the HERO Registry and the HERO-HCQ Trial. The HERO Registry is asking hundreds of thousands of U.S. healthcare professionals to join, including nurses, therapists, physicians, emergency responders, food service workers, environmental services workers, interpreters, and transporters anyone who…
Condition: Transplant
Investigator: Ran Reshef, MD
Status: Closed
This research trial is designed to study the safety and effectiveness of combining the study drug, Natalizumab (Tysabri) with the standard treatment, the use of steroids, as a new treatment for acute graft versus host disease (acute GVHD). GVHD is the most common serious complication, after bone marrow transplant. GVHD occurs when the donor cells (the graft…